- Home
- INMB vs ORKT Comparison
INMB vs ORKT Comparison
Compare INMB & ORKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ORKT
- Stock Information
- Founded
- INMB 2015
- ORKT 2003
- Country
- INMB United States
- ORKT Singapore
- Employees
- INMB N/A
- ORKT N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ORKT
- Sector
- INMB Health Care
- ORKT
- Exchange
- INMB Nasdaq
- ORKT NYSE
- Market Cap
- INMB 103.1M
- ORKT 82.9M
- IPO Year
- INMB 2019
- ORKT 2024
- Fundamental
- Price
- INMB $6.53
- ORKT $0.71
- Analyst Decision
- INMB Strong Buy
- ORKT
- Analyst Count
- INMB 2
- ORKT 0
- Target Price
- INMB $21.00
- ORKT N/A
- AVG Volume (30 Days)
- INMB 369.6K
- ORKT 3.7M
- Earning Date
- INMB 10-31-2024
- ORKT 10-16-2024
- Dividend Yield
- INMB N/A
- ORKT N/A
- EPS Growth
- INMB N/A
- ORKT N/A
- EPS
- INMB N/A
- ORKT N/A
- Revenue
- INMB $42,000.00
- ORKT $3,904,592.00
- Revenue This Year
- INMB N/A
- ORKT N/A
- Revenue Next Year
- INMB N/A
- ORKT N/A
- P/E Ratio
- INMB N/A
- ORKT N/A
- Revenue Growth
- INMB N/A
- ORKT N/A
- 52 Week Low
- INMB $4.32
- ORKT $0.68
- 52 Week High
- INMB $14.74
- ORKT $8.00
- Technical
- Relative Strength Index (RSI)
- INMB 64.22
- ORKT N/A
- Support Level
- INMB $6.04
- ORKT N/A
- Resistance Level
- INMB $6.83
- ORKT N/A
- Average True Range (ATR)
- INMB 0.56
- ORKT 0.00
- MACD
- INMB 0.17
- ORKT 0.00
- Stochastic Oscillator
- INMB 86.76
- ORKT 0.00
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About ORKT ORANGEKLOUD TECHNOLOGY INC
Orangekloud Technology Inc is a company that operates through its subsidiaries provide IT consultancy services and distribution of related products and services. The Company also offers ERPs predominately in Singapore. It derives revenue from platform subscriptions, license and products and professional services.